30.6 C
Vientiane
Wednesday, September 10, 2025
spot_img
Home Blog Page 459

Seegene unveils the world’s first unattended PCR automation, igniting a global diagnostic paradigm shift at ADLM 2025

  • Fully Unmanned— CURECA™, the 100% Automated Diagnostic System Defining the Future Gold Standard, Debuts in Chicago, July 28–31
  • Unifying global diagnostic data – STAgora™, the big data platform set to transform the future of diagnostics
  • Pilot partnerships to offer early access to the new diagnostic paradigm, with selected institutions engaged by year-end

SEOUL, South Korea, July 23, 2025 /PRNewswire/ — Seegene Inc., a global leader in molecular diagnostics, announced today that it will unveil its fully automated PCR testing system, CURECA™, and its data analytics platform, STAgora™, at ADLM 2025 (Association for Diagnostics & Laboratory Medicine), the world’s largest diagnostics conference, taking place in Chicago from July 28 to 31. With the introduction of these new technologies, Seegene declares a transformative shift in the global diagnostics paradigm.

Seegene will present a live demonstration of CURECA™ (pictured), its next-generation fully automated PCR testing system in ADLM 2025, held in Chicago from July 28 to 31. CURECA™ integrates three core modules: a prep module for pre-analytical processing, a diagnostic module for assay execution, and a software module for data analysis.
Seegene will present a live demonstration of CURECA™ (pictured), its next-generation fully automated PCR testing system in ADLM 2025, held in Chicago from July 28 to 31. CURECA™ integrates three core modules: a prep module for pre-analytical processing, a diagnostic module for assay execution, and a software module for data analysis.

Automating every step of PCR Testing for enhanced efficiency and accuracy

CURECA™ is the world’s first system to fully automate the entire PCR testing process – from specimen storage and pre-treatment to nucleic acid extraction, amplification, and result analysis – without any human intervention. Designed for 24/7 continuous operation, the system minimizes human error and dramatically improves the consistency and reliability of the test results.

A key breakthrough lies in its fully automated prep module, which addresses one of the most burdensome and error-prone stages in diagnostic workflows. Pre-treatment has traditionally been a major challenge, particularly when dealing with diverse sample types such as urine, blood, sputum, and stool. Lab technicians often carry out repetitive manual tasks over extended hours, and variations in skill level can result in inconsistent outcomes. Stool samples, especially, have posed serious automation barriers due to their viscosity and particulates, requiring heavy manual handling.

The prep module of CURECA™ system is the first to fully automate pre-treatment process across all major specimen types – including stool – overcoming longstanding obstacles in laboratory operations. This innovation reduces labor demands, expands sample throughput, and enhances overall operational and cost efficiency. It also shifts the role of laboratory personnel from manual processing to higher-level responsibilities, such as data analysis and clinical interpretation – helping labs better leverage their workforce in high-volume testing environments.

In addition, the prep module is applicable beyond PCR diagnostics. It supports pre-treatment for other disciplines, including clinical chemistry and immunoassays, marking a significant step forward in automation across the broader diagnostics market. Its modular architecture allows for flexible configuration and deployment tailored to the size, layout, and needs of each laboratory.

STAogra – Real-Time Global Data Integration Empowering Personalized Care

Also unveiled at ADLM 2025, STAgora™ is Seegene’s statistical platform that collects and analyzes real-time PCR diagnostic data to support clinical decision-making. By aggregating test data uploaded from hospitals around the world, the platform provides integrated insights into regional infection trends, hospital-level positivity rates, and patterns of co-infection. It also offers more than 40 statistical tools tailored for clinical support.

With STAgora™, healthcare providers can compare individual patient test results with local and regional epidemiological data, enabling more precise, data-driven treatment strategies. The platform allows clinicians to evaluate infection trends at both patient and community levels, improving the accuracy and speed of diagnosis and care planning. By delivering rapid, reliable insights through this kind of comprehensive analysis, STAgora™ is expected to become an essential analytical tool for clinical decision-making.

Expanding Global Collaboration via Technology Sharing and Strategic Partnerships

Building on its presence at ADLM 2025, Seegene aims to broaden access to CURECA™ and STAgora™ by offering early pilot experiences and establishing new global partnerships.

Earlier this year, CURECA™ attracted strong interest at ESCMID Global 2025, one of Europe’s leading clinical microbiology and infectious disease congresses. To strengthen its R&D and manufacturing capacity in the United States, Seegene has established local subsidiaries, including Seegene Technologies and Seegene CURECA.

“CURECA™ and STAgora™ are more than just diagnostics equipment or software—they represent a new global standard that will redefine diagnostics in clinical settings around the world. We will continue to share the many technological assets we’ve built over the years and based on this foundation, we are committed to driving fundamental innovation across the global diagnostics ecosystem.” Said Daniel Shin, Executive Vice President, Chief of Global Sales & Marketing at Seegene.

Disclaimer

The product is currently in a pre-commercialization phase. The configuration presented at ADLM 2025 is for demonstration purposes only and may differ in functionality, specifications, and components from the final commercial version. This material is intended solely to introduce the technology and does not constitute an advertisement for product sales.

About Seegene

Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene’s syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information.

Visit: Seegene.com and follow linkedin.com/company/seegene-inc

AVer Receives Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Medical-Grade PTZ Cameras

Recognized for its AI-driven innovation, platform-agnostic product design, and exceptional customer-centric healthcare video solutions

SAN ANTONIO, July 23, 2025 /PRNewswire/ — Frost & Sullivan is pleased to announce that AVer Information Inc. has received the 2025 Global Company of the Year Recognition in the medical-grade PTZ cameras industry for its outstanding achievements in technology innovation, healthcare-focused strategy execution, and customer impact. This recognition highlights AVer’s consistent leadership in driving measurable outcomes, strengthening its market position, and delivering customer-centric innovation in an evolving competitive landscape.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. AVer excelled in both, demonstrating its ability to align strategic initiatives with market demand while executing them with efficiency, consistency, and scale. “AVer is right in the middle of a significant transformation in healthcare delivery, with products and services that enable and positively contribute to this change,” said David Frigstad, Chairman at Frost & Sullivan.

Guided by a long-term growth strategy focused on AI-driven innovation, platform-agnostic product design, and healthcare collaboration, AVer has shown its ability to adapt and lead in a rapidly evolving landscape. The company’s strategic agility and sustained investment in connected healthcare solutions have enabled it to scale effectively across clinical and homecare environments.

Innovation remains central to AVer’s approach. Its suite of medical-grade PTZ cameras addresses the full spectrum of telehealth, tele-ICU, tele-sitting, and remote patient monitoring needs, offering seamless integration, scalability, and high-performance video capabilities. “We are thrilled to receive this prestigious award from Frost & Sullivan, one of the leading research firms in the healthcare industry,” said Andy Hsi, CEO, AVer Information Inc. “AVer as a company is committed to making a positive difference in the revolutionary telehealth industry, empower smart healthcare environments and help create better patient outcomes for caregivers with our AI and video innovations.”

AVer’s unwavering commitment to customer experience further strengthens its position in the market. By offering robust support resources—such as training videos, comprehensive manuals, and localized expert assistance via phone, email, or video conferencing—the company ensures that every implementation is successful. Its platform-agnostic camera designs simplify deployments across diverse healthcare settings, enhancing adoption and long-term value.

Frost & Sullivan commends AVer for setting a high standard in competitive strategy, execution, and market responsiveness. The company’s vision, innovation pipeline, and customer-first culture are shaping the future of connected healthcare and driving tangible results at scale.

Each year, Frost & Sullivan presents the Company of the Year Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. It recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence.

Frost & Sullivan Best Practices recognitions honor companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Camila Tinajero
E: camila.tinajero@frost.com  

About AVer Information Inc.

Founded in 2008, AVer is an award-winning provider of education technology, healthcare and video collaboration camera solutions that improve productivity and enrich learning. From accelerating learning in the classroom, safely supporting patient care, to increasing competitive advantage for businesses, AVer solutions leverage the power of technology to help people connect with one another to achieve great things. Our product portfolio includes Professional Grade Artificial Intelligence Enabled Auto Tracking Cameras, Medical Grade PTZ Cameras, Zoom and Microsoft Teams Certified Enterprise Grade USB Cameras, Document Cameras and Classroom Audio Solutions. We strive to provide industry leading service and support that exceeds our customer’s expectations. We are also deeply committed to our community, the environment and employ stringent green processes in all we do.

HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma

  • Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma, with an initial data readout expected in mid-2026
  • HBM9378/WIN378 has the potential to be the first-to-market long-acting anti-TSLP antibody with twice-yearly dosing for asthma
  • Extended dosing intervals could reduce treatment burden and improve outcomes for patients with advanced respiratory diseases 
  • Global COPD clinical program planned to start in mid-2026

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI, July 23, 2025 /PRNewswire/ — Harbour BioMed (the “Company”; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that its partner, Windward Bio AG (“Windward Bio”), has initiated the POLARIS clinical study, a global, randomized, double-blind, placebo-controlled Phase 2 study evaluating the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma. Initial data are expected in mid-2026.

Asthma is a chronic respiratory condition affecting approximately 300 million people worldwide, with prevalence continuing to rise. Despite the availability of treatment options, many patients experience persistent symptoms, frequent exacerbations, and reduced quality of life. Current therapies – mainly inhaled corticosteroids (ICS) and bronchodilators – are inadequate for some patients, underscoring the urgent need for more effective, long-acting treatments that address the underlying disease mechanisms.

HBM9378/WIN378 is a potentially best-in-class, long-acting monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), a well-validated cytokine that plays a key role in the development and progression of a wide array of immunological diseases, including asthma and chronic obstructive pulmonary disease (COPD). This molecule has fully human sequences, offering a lower risk of immunogenicity and improved bioavailability compared to other TSLP-targeting therapies. It has been engineered to achieve a half-life extension and a silenced effector function and is subcutaneously administered. In a Phase 1 trial, HBM9378/WIN378 demonstrated an extended half-life, showed a low incidence of antidrug antibodies, and was safe and well tolerated up to the highest tested dose.

“We are pleased to see HBM9378/WIN378 advancing rapidly into global clinical development,” said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. “This long-acting, fully human anti-TSLP antibody has demonstrated strong potential in previous preclinical and clinical studies. We believe it has the potential to address significant unmet needs for patients with asthma.”

HBM9378/WIN378 (also known as SKB378) started as a co-development project jointly conducted by Harbour BioMed and Kelun-Biotech, with both parties equally sharing global rights. Earlier this year, Harbour BioMed and Kelun-Biotech entered into a strategic partnership with Windward Bio, granting Windward Bio an exclusive license to research, develop, manufacture, and commercialize this antibody globally, excluding Greater China and several Southeast and West Asian countries.

In addition to asthma, HBM9378/WIN378 is also being evaluated in clinical trials for COPD, another major respiratory condition. In November 2024, the Company submitted an Investigational New Drug (IND) application for HBM9378/WIN378 in COPD to the National Medical Products Administration (NMPA) of China, which was approved in January 2025. Additionally, Windward Bio plans to initiate global clinical trials in COPD in 2026. The continued progress of HBM9378/WIN378 in both asthma and COPD highlights the versatility and potential of this innovative therapy.

About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.

Harbour BioMed’s proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com.

About Windward Bio AG
Windward Bio is a clinical-stage biotechnology company with deep discovery, development and commercialization expertise committed to transforming the treatment of people living with advanced immunological conditions. Its lead program is WIN378, a potential best-in-disease, long-acting, anti-TSLP monoclonal antibody in Phase 2 for asthma. The company is planning additional clinical studies of WIN378 in COPD and other respiratory indications and is also building a pipeline of long-acting bi-specific antibodies targeting validated biology in respiratory and dermatological conditions. Windward Bio launched earlier this year with a $200M Series A led by top-tier investors.

 

CeraVe Celebrates Two Decades of “Developed with Dermatologists” Skincare: A 20th Birthday Tribute to Skin Barrier Science and Innovations

A Global Celebration Unites Dermatologists, Influencers, and Innovators in New York City to Mark 20 Years of the Iconic Skincare Brand

NEW YORK, July 23, 2025 /PRNewswire/ — It’s CeraVe-time to celebrate! CeraVe, the global skincare brand recommended by 80,000 dermatologists worldwide1, is celebrating a major milestone: 20 years of skin barrier authority, championing barrier health and delivering effective, skin identical ceramide and MVE solutions to provide accessible, therapeutic skincare solutions for everybody everywhere.

Over the past two decades, CeraVe has catapulted from a local US derm-backed secret to a global phenomenon, building an inclusive brand that appeals to all genders and generations. What remains unchanged is the brand’s foundational insights: that most skin issues are linked to skin barrier disruption, and that skin identical ceramides are key to restoring and maintaining it. That insight began with three core products: Moisturizing Cream, Moisturizing Lotion and Hydrating Cleanser, and today powers a global portfolio of more than 90 barrier-supporting products. This unwavering dedication to its foundational insights, supported by its expertise as a skin barrier authority and its dermatologist-led development, has been the driving force behind CeraVe’s remarkable exponential expansion, leading to an impressive 10X growth since its inception, and crossing the $2 billion mark in global sales last year.

From the very beginning, CeraVe has revolutionized the skincare landscape as the first brand to be developed with dermatologists – not as a slogan, but as a guiding philosophy and scientific foundation. Every formula, every innovation, every product begins and ends with the expertise of dermatologists, from concept to counter (or store shelf); ensuring clinical efficacy, barrier health and results.

“CeraVe’s journey began and continues with dermatologists, ensuring superior skin health for all,” said Melanie Vidal, Global General Manager, CeraVe. “Through close collaboration, we’ve transformed their groundbreaking clinical insights into widely accessible, therapeutic solutions that truly enhance lives. As we celebrate two decades of CeraVe and our significant expansion into over 65 countries, we are more dedicated than ever to formulating trusted, barrier-focused products, developed in partnership with dermatologists, for every individual. This momentous occasion not only honors our past achievements but also ignites our drive for another twenty years of pioneering global skin health and advancing the science of the skin barrier.”

Key to CeraVe’s success is the unique formulation that pairs three skin-identical ceramides with trademarked MVE technology – a unique delivery system that releases ingredients gradually, providing hydration that goes 10 layers deep and lasts all day. From the beloved intense hydration of the AM & PM Facial Moisturizing Lotion for dry skin or the barrier-friendly approach of the new Anti-Dandruff Hydrating Shampoo and Conditioner, each product is a direct result of clinical insight and consumer need. This dedication to tailored, dermatologist-developed solutions, consistently infused with ceramides and MVE technology, is why CeraVe has earned such profound trust and widespread recommendations from skin health professionals worldwide. Indeed, in the US and Canada, CeraVe proudly holds the #1 recommended position among key healthcare professionals, including dermatologists, pharmacists, and pediatricians2, underscoring its broad acceptance and efficacy across various medical specialties.

To celebrate this significant accomplishment, CeraVe hosted a global celebration: a birthday bash in New York City that brought together some of the world’s most-followed dermatologists, including Dr. Muneeb Shah, Dr. Mamina Turegano, Dr. Evan A. Rieder, Dr. Ted Lain, Professor Michael Cork, Dr. Esther Freedman, Dr. Dustin Portela, Dr. Wallace Nozile, Dr. Zoe Draelos, Dr. Nkem Ugonabo, Dr. Oyetewa Asempa, Dr. Leena Ramani, and Dr. Toral Vaidya, as well as some of TikTok’s biggest stars, including Charli D’Amelio (@charlidamelio), and Ari@Home (@ariatinsta). The event was held on World Skin Health Day, allowing CeraVe to further amplify its message of accessible, dermatologist-developed skincare and its dedication to improving skin health worldwide, particularly through its commitment to providing access to dermatological care in under-resourced communities through the brand’s Care For All social impact program.

As CeraVe looks to the future, the brand remains steadfast in its commitment to dermatologist-developed, science-backed skincare solutions; it continuously pushes the boundaries of innovation. Recent launches highlight groundbreaking new formats within their comprehensive portfolio. For instance, the transformative Blemish Clay-to-Foam Cleanser offers a 3-in-1 solution for blemish-prone skin; it visibly reduces pimples and post-acne marks in just three days. The gentle cleansing Balancing Air Foam Facial Cleanser, designed for combination skin, features Breakthrough Glycolysine™ Technology, providing 8-Hour Oil Control and 24-Hour Hydration. Additionally, CeraVe Blemish Barrier Patches are now available; these leverage advanced hydrocolloid technology with 3 essential ceramides and niacinamide, visibly flattening blemishes in 3 hours, absorbing excess oil, and helping prevent post-acne marks. These innovations collectively underscore CeraVe’s dedication to accessible and cutting-edge skincare for all. Beyond skincare, CeraVe marked a significant milestone in the past year by successfully entering the brand new hair care category with its Anti-Dandruff and Gentle Haircare lines. The CeraVe Anti-Dandruff Shampoo and Conditioner when used as a system eliminates up to 100% of visible flakes without disrupting the scalp barrier, while also alleviating symptoms of mild to moderate dandruff and leaving hair healthy and soft. This bold venture has notably been recognized as the most successful hair care launch according to Nielsen data3.

“As one of the first dermatologists involved in the development of CeraVe, I am proud to be part of a brand that has held true to their clinical roots,” said Dermatologist Dr. Zoe Draelos. “CeraVe remains committed to involving dermatologists in the development and testing process – that’s why it’s one of the most effective skincare brands.  It will be exciting to see the future brand innovations, as my fellow dermatologists continue to seek out accessible, beneficial skincare products for all.” 

Beyond its scientific rigor, CeraVe has consistently engaged its audience through its signature “medutainment” style – a unique blend of education and entertainment – with a series of noteworthy campaigns over the past two decades. From the iconic Michael CeraVe Super Bowl commercial that playfully embraced the brand’s name, to the destigmatizing of dandruff with the “Head of CeraVe” campaign, and most recently, its Sarah V. GOAT mascot, CeraVe has masterfully utilized these platforms to get its core messaging across and re-emphasize its status as a brand developed with dermatologists.

1Source: Survey conducted among the dermocosmetic market carried out by APLUSA and its other partners between January 2024 and May 2024, involving dermatologists in 29 countries

2Source: The #1 recommended positions are supported by the following:

  • US Dermatologists: CeraVe is the #1 recommended position among dermatologists in the US. Source: IQVIA, ProVoice Survey, rolling 12-month data as of January 2025.
  • US Pharmacists: CeraVe is the #1 Pharmacist Recommended Skincare Brand in US. Based on an independent national survey of pharmacists, June 2025.
  • US Pediatricians: CeraVe is the #1 Pediatrician Recommended Skincare Brand in US. Based on ProVoice National Pediatrician Survey, June 2024.
  • Canada Healthcare Professionals: CeraVe is the N°1 General Practitioners (or Doctor) recommended brand, N°1 Pediatricians recommended brand, N°1 Pharmacists recommended brand, and N°1 Healthcare Professionals recommended brand in Canada. Source: IQVIA, Provoice Survey Q2 2024 – Q1 2025.

3Source: Nielsen Data

About CeraVe: 
Founded in 2005 and developed with dermatologists, CeraVe is the first and only brand to offer a complete line of products containing essential ceramides and MVE technology to help restore the skin’s natural protective barrier. CeraVe has a full line of skincare products to follow the dermatologist-recommended steps of: cleanse, treat, moisturize and protect. The brand’s mission is to provide therapeutic skincare for all. For more information, visit the brand on Facebook (@ceraveusa), Instagram (@cerave), TikTok (@cerave), X (@cerave) or at www.cerave.com.

Contact: 

Mia Kain                                 

Daria Sprague

CeraVe                                               

Ogilvy

mia.kain@loreal.com             

daria.sprague@ogilvy.com

 

Dr. Ted Lain and Tom Allison
Dr. Ted Lain and Tom Allison

 

CeraVe 20th Birthday Panel
CeraVe 20th Birthday Panel

 

Dr. Dustin Portela
Dr. Dustin Portela

 

Dr. Ted Lain
Dr. Ted Lain

 

CeraVe 20th Birthday Attendees
CeraVe 20th Birthday Attendees

 

 

Bybit DeFi Report: RWA and DEXs Thrive Despite Cooling Market Activity

DUBAI, UAE, July 23, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, released a new decentralized finance (DeFi) report, encapsulating significant shifts in the sector with real-world assets (RWA) and decentralized exchanges (DEXs) as new drivers. Unlike the frenzy of DeFi Summer of 2020, institutional adoption and utility-focused applications are fueling today’s market.

Key Insights

  • DeFi’s Institutional Play: Regulatory clarity stemming from events such as the GENIUS Act and Circle’s IPO has spurred institutional interest in DeFi lending and tokenized assets. Backed by the mainstreaming of stablecoins, DeFi’s integration with traditional finance has been driven by institutional interest. Total DeFi lending deposits reached $67.8 billion across platforms including Aave, Morpho, and Maple Finance. RWA platforms like Securitize, Ondo Finance, and Franklin Templeton are enabling yield opportunities backed by US Treasuries, bridging crypto and mainstream investing.
  • DEXs Challenge Centralized Players: Hyperliquid leads perpetual futures trading with $1.27 trillion in year-to-date volume, showing DEXs can play in the same league as CEXs. This has encouraged hybrid platforms like Byreal, which combine CEX liquidity with DeFi transparency.
  • Divergent Performance: While RWA and DEX sectors flourish, AI-related DeFi (DeFAI) tokens face declining interest and liquid staking growth remains constrained by token volatility.

Source: Bybit, CoinGecko
Source: Bybit, CoinGecko

The report approaches the state of play in DeFi with sector highlights from all aspects,  demonstrating DeFi’s transition toward utility-focused applications anchored in real-world use cases. As institutional RWA adoption accelerates and hybrid solutions emerge, DeFi positions itself as on-chain financial infrastructure, combining centralized finance performance with decentralized transparency.

#Bybit / #TheCryptoArk / #BybitReport

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

Ascenda Elevates 2-Sided Commerce Network with Appointment of Top-Tier Bank Leader Abeer Bhatia

Bhatia joins Ascenda following senior roles at American Express, Chase, and Wells Fargo to grow the company’s ecosystem of financial institutions and merchants into an unprecedented 2-sided commerce network powering transformational marketing outcomes

NEW YORK, July 23, 2025 /PRNewswire/ — Ascenda, the loyalty company that powers growth for the world’s leading brands, today announced the appointment of Abeer Bhatia as President, Strategy & Growth, to help spearhead its 2-sided network strategy and business development.

This senior-level addition underscores Ascenda’s commitment to driving transformational outcomes for top-tier banks and large merchants in ways that bust through the limitations of established rewards marketing models.

Bhatia is a distinguished payments and consumer banking executive with experience spanning two decades of senior leadership roles, having conceived and built many of the industry’s most impactful rewards propositions at the largest scale. At American Express, he led the pioneering acquisition of Loyalty Partner / Payback and rapid expansion of everyday rewards programs across tens of millions of customers globally. At JPMorgan Chase, he conceptualized and executed the bank’s entry into merchant advertising with Chase Offers, alongside other groundbreaking product launches such as Credit Journey, MyChaseLoan, and MyChasePlan. And most recently, at Wells Fargo, he helped drive innovation and growth with products like Flex Loan and as CEO Personal Lending & Enterprise Payments.

“Abeer’s track record of conceiving and launching transformational propositions that unlock value for financial institutions, customers, and merchants aligns perfectly with our vision to scale,” said Kyle Armstrong, CEO of Ascenda. “This appointment catapults us forward as we work to deliver radically bigger outcomes for our largest clients.”

“I am thrilled to join Ascenda at this pivotal moment in the evolution of financial services,” said Bhatia. “Forward-thinking banks are looking to innovate and create new, differentiated value propositions while fundamentally improving economics. Ascenda’s global two-sided commerce ecosystem is the ideal platform to transform bank-merchant marketing to deliver significantly greater customer value and financial returns for network participants.”

About Ascenda

Ascenda powers many of the world’s most iconic financial services products, enabling high-value, personalized rewards experiences that drive profitable behavior. With over a decade of proven results, an unrivaled roster of top-tier global clients, and enterprise-grade technology, Ascenda is trusted by leading brands to deliver growth outcomes, eliminate complexity, and create extraordinary customer experiences. For more information, please visit ascenda.com

 

South Africans living in Australia and New Zealand can now avail passport, ID, and birth registration services with ease

  • VFS Global expands passport, ID, and birth registration service capabilities with new renewal centres for South African citizens in Auckland and Wellington in New Zealand and Sydney and Melbourne in Australia
  • VFS Global is the official outsourcing partner for the DHA Services Centre for consular services in Australia and New Zealand for the Republic of South Africa

AUCKLAND, New Zealand and SYDNEY, July 23, 2025 /PRNewswire/ — With many South African nationals residing outside of their home country, the need for easy direct access to government and consular services is becoming more imperative than ever before. To deliver this service, the Home Affairs Department has extended its partnership with VFS Global to launch passports, ID, and birth registration services in Australia and New Zealand with newly opened centres in Auckland and Wellington in New Zealand and Sydney and Melbourne in Australia.

Inauguration of South Africa DHA Services Centre in Sydney by Honourable Minister of Home Affairs for the Republic of South Africa Dr. Leon Schreiber (first from right)
Inauguration of South Africa DHA Services Centre in Sydney by Honourable Minister of Home Affairs for the Republic of South Africa Dr. Leon Schreiber (first from right)

The DHA Services Centre in Auckland (New Zealand) was inaugurated on 15 July 2025 by H.E. Mr. Johnny Sexwale, South African High Commissioner to New Zealand on behalf of the Minister of Home Affairs, while the Sydney and Melbourne (Australia) were inaugurated on 16 July 2025 and 18 July 2025, respectively, by Honourable Minister of Home Affairs for the Republic of South Africa Dr. Leon Schreiber. The DHA Services Centre in Wellington has also started operations.

By leveraging scalable and intuitively designed services in the passport application and consular services domain, VFS Global delivers on a range of key requirements from online appointment booking and customer support to front-office services, biometric enrolment and doorstep return-delivery of passports and other documentation requirements.

Jiten Vyas, Chief Commercial Officer, VFS Global, added, “We would like to thank the Department of Home Affairs in the Republic of South Africa for its continued faith in us. Our focus and commitment will be to provide world-class service to the South African diaspora in Australia and New Zealand to ease the passport renewal process for South African nationals.”

Australia:

  • Melbourne: Level 5, 332 St Kilda Road, Melbourne 3004
  • Sydney: Level 6, 88 Pitt Street, Sydney, NSW 2000
  • Business hours: 9AM to 5PM

New Zealand:

  • Auckland: Huawei Center, Level 8, 120 Albert Street, Auckland CBD, Auckland 1010
  • Wellington: Level 6, 50 Manners Street, Te Aro, Wellington 6011
  • Business hours: 9AM to 4PM

For more, visit:

Infosys: Industry-leading Sequential Growth of 2.6% in CC, Driven by Differentiated Value Proposition in Enterprise AI

– Large Deal Wins at $3.8 Billion with 55% Net New; Demonstrating Deep Competitive Advantage in Consolidation Play
– FY26 Revenue Guidance Revised to 1%-3% and Margin Guidance Retained at 20%-22%

BENGALURU, India, July 23, 2025 /PRNewswire/ — Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation digital services and consulting, delivered $4,941 million in Q1 revenues, year-on-year growth of 3.8% and sequential growth of 2.6% in constant currency. Operating margin was at 20.8%. Free cash flow generation was strong at $884 million, 109.3% of net profit. TCV of large deal wins was $3.8 billion, with 55% net new. ROE improved by 140 bps to 30.4%.

“Our performance in Q1 demonstrates the strength of our enterprise AI capabilities, the success in client consolidation decisions, and the dedication of our over 300,000 employees,” said Salil Parekh, CEO and MD. “Our large deal wins of $3.8 billion reflect our distinct competitive positioning and deep client relationships,” he added.

2.6% QoQ
3.8% YoY 
CC Growth  

20.8% 
Operating Margin

8.6% YoY
EPS Increase 
(₹ terms)

$3.8 Bn 
Large Deal TCV
(55% Net New)

$884 Mn 
Free 
Cash Flow

Guidance for FY26:

  • Revenue growth of 1%-3% in constant currency
  • Operating margin of 20%-22%

Key highlights:

For the quarter ended June 30, 2025

  • Revenues in CC terms grew by 3.8% YoY and by 2.6% QoQ
  • Reported revenues at $4,941 million, growth of 4.8% YoY
  • Operating margin at 20.8%, decline of 0.3% YoY and decline of 0.2% QoQ
  • Basic EPS at $0.20, increase of 5.8% YoY
  • FCF at $884 million, decline of 19.2% YoY;
    FCF conversion at 109.3% of net profit

“Q1 performance is a clear reflection of our unwavering focus on multiple fronts resulting in strong growth at 2.6% QoQ, resilient margins at 20.8% and EPS increase of 8.6% YoY. We continue to leverage Project Maximus to make investments in strategic priorities to drive profitable growth and enhance shareholder value,” said Jayesh Sanghrajka, CFO. “Cash flow conversion was well above 100% for the fifth consecutive quarter. The impact of currency volatility was effectively managed through our proactive hedging strategy,” he added.

Client wins & Testimonials

  1. Infosys announced the extension of its strategic collaboration with Select Portfolio Servicing, Inc. (SPS) to help drive greater operational efficiency and service quality through a fully managed services offering encompassing hybrid cloud solutions, application portfolio, IT operations, IaaS, SaaS, security operations and quality assurance. Murali Palanganatham, Chief Information Officer, SPS, said, “Infosys has been a key strategic partner over the last 20 years. SPS will leverage Infosys Topaz for AI adoption across the business, technology, and enterprise functions to continuously enhance availability, scalability, performance, resiliency, security, and stability. This collaboration is critical and will help SPS enhance flexibility, efficiency, and predictability of our technology ecosystem.”
  2. Infosys extended its strategic collaboration with AIB to accelerate its digital transformation initiatives. Graham Fagan, Group Chief Technology Officer, AIB, said, “This extended collaboration with Infosys aligns strongly with our vision to progressively modernise our technology and data capabilities to deliver the best outcomes for our customers and further accelerate our transformation. By combining our collective expertise and experience, we will deliver on our customer-first commitment and enhance operational efficiency and resilience. Infosys has been a trusted innovation partner, and we are excited about this next chapter in our collaboration as we work together to ensure AIB remains at the forefront of digital transformation in the Irish banking industry.” 
  3. Infosys announced a strategic collaboration with E.ON to enable AI-powered digital workplace transformation across Europe. Dr. Victoria Ossadnik, COO Digital and Innovation, E.ON, said, “At E.ON, we are playmakers for new energy. Digitalization and digital technology are key for reliable, affordable and sustainable energy systems. Our strategic partnership with Infosys is essential for our digital transformation and operation – together, we are paving the way for a smarter, more efficient energy future.”
  4. Infosys announced the expansion of its strategic collaboration with DNB Bank ASA (DNB) to accelerate the bank’s digital transformation. Elin Sandnes, COO and Group Executive Vice President Technology & Services, DNB, said, “At DNB, we are focused on leveraging technology to create great customer experiences. As part of this, we are constantly developing new products and services while simultaneously driving a digital transformation agenda that is deeply rooted across all our operations. With our extended collaboration with Infosys, we are modernizing our IT infrastructure and leveraging advanced technologies like AI and ML to enable seamless, personalized, and agile services to our customers. This partnership allows us to proactively address our customers’ evolving needs and ensure they receive the best possible banking experience from DNB.”
  5. Infosys announced a strategic collaboration with Yorkshire Building Society, one of the largest member-owned financial institutions in the UK, to accelerate its digital transformation. Patrick Connolly, Director of Change Delivery, Yorkshire Building Society, said, “This collaboration is crucial to achieving our 2030 ambitions and realising the true potential of this organisation. The choices we make now will shape our future, and we are committed to combining the convenience of digital with the warmth of human interaction. This transformation will empower our members and colleagues with the tools and services needed to deliver great customer outcomes, including major investments such as faster payments and enhanced security. It’s a key part of our plan for continued growth, innovation, and efficiency, ensuring we continue to serve our members for generations to come.”
  6. Infosys and Spark New Zealand announced a strategic agreement to support the transformation of Spark’s technology delivery model through digital innovation. Matt Bain, Data and Marketing Director, Spark, said, “Infosys has collaborated with Spark for over 16 years, working alongside our local teams to support the applications that enable Spark to deliver new products and digital experiences for our customers. We are now building on this relationship to allow our teams to focus on our technology strategy and the product roadmaps that will grow our competitive advantage, while leveraging Infosys’ global scale to execute these plans quickly and efficiently and accessing Infosys’ investment in AI and innovation to enable us to keep delivering great experiences for our customers.”
  7. Infosys collaborated with Perfection Fresh to enable seamless tracking of their sustainability efforts. Francesco Oliveri, Chief Information Officer, Perfection Fresh Australia, said, “Our Partnership with Infosys to implement Microsoft Sustainability Manager has helped us in providing real-time visibility of produce across all locations thereby improving operational efficiency, audit transparency and reducing wastage. Originally planned for just 4 sites, the rollout extended to all 17 locations thanks to Infosys’ expertise and collaboration. It was also their vision and commitment to sustainability that matched our vision that allowed us to be more comfortable in working with Infosys. The partnership has been instrumental in driving key milestones for Perfection Fresh’s sustainability roadmap.”
  8. Infosys Finacle announced a strategic collaboration with Bank of Sydney (BoS) to power its digital transformation with Infosys Finacle Digital Banking Suite. Melos Sulicich, Chief Executive Officer, Bank of Sydney, said, “At Bank of Sydney, our strategic goal is to become the leading deposit bank in Australia and to drive significant business growth in the coming years. This requires adapting to rapidly changing customer needs, digital advancements, and regulatory requirements. Transforming our technology stack, centered around our core and digital banking platform, is crucial to meeting these objectives. With Infosys Finacle, we have a proven transformation partner and a next-generation banking platform to address the evolving needs of our business, customers, and regulatory ecosystem.”
  9. Infosys BPM announced the launch of AI agents for invoice processing within its flagship Infosys Accounts Payable on Cloud solution. Harsh Bansal, Chief Financial Officer and Chief Growth Officer, Americana Restaurants, said, “At Americana Restaurants, we are committed to leading digital transformation, and as we scale our operations, intelligent automation is key to achieving greater efficiency and agility. With AI-powered Infosys Accounts Payable on Cloud, we have made invoice processing faster, enhanced accuracy, and improved efficiency. The addition of Agentic AI takes this a step further, reducing manual dependencies and bringing more intelligence and autonomy into our invoice processing. We are delighted that we have pioneered this initiative with Infosys and look forward to closely working with Infosys BPM to lead us collectively into a future of smarter and more agile operations.”
  10. Infosys announced a three-year strategic collaboration with the Lawn Tennis Association (LTA) to deliver a range of AI-powered innovations, including match insights and immersive fan experiences. Chris Pollard, Managing Director, Commercial & Operations, LTA, said, “We are incredibly excited to witness the historic moment of the HSBC Championships at Queen’s Club hosting both WTA and ATP 500 events for the very first time. This milestone marks a significant step in the growth and evolution of this prestigious tournament. We are thrilled to collaborate with Infosys, whose support will be instrumental in delivering an enhanced fan experience. Infosys’ AI and technology innovations will bring a new level of engagement with real-time insights and interactive moments, creating memorable experiences for our fans and contribute to the continued success of the HSBC Championships.”
  11. Infosys and Economist Impact announced the launch of The Sustainability Atlas to help businesses navigate a sustainable future. Jonathan Birdwell, Global Head of Policy & Insights, Economist Impact, said, “Over the past decade, Economist Impact has built dozens of indices and published hundreds of reports across a wide range of sustainability topics from food security to plastics management, to climate resilience. But never before have we been able to bring all of that data and insights together in one place. Leveraging Infosys’ generative AI capabilities, The Sustainability Atlas provides easily accessible and actionable insights to policy makers and business leaders worldwide.”

Recognitions & Awards

  • Brand & Corporate
    • Recognized as a Top 100 most valuable brand in the world by Kantar BrandZ and ranked among the most-trusted brands in India and the US
    • Recognized as one of the top 3 companies (on combined basis) in 5 categories – Best CEO, Best IR Professional, Best IR Program, Best IR Team and Best ESG Program – at the 2025 Asia Executive Team Survey by Extel (formerly Institutional Investor Research)
    • Recognized as a Great Place to Work 2025-2026 in India and China
    • Infosys BPM won at the Diversity Charter Awards 2025 in the ‘Employer Supporting Women in the Workplace’ category for its HR initiative, namely ‘Empower with Care’
    • Infosys BPM won the PeopleFirst HR Excellence Awards 2025 for ‘Leading Practices’ in Learning & Development
  • Digital, AI and Cloud Services
    • Positioned as a leader in the Everest Group: Microsoft Modern Work Services PEAK Matrix® Assessment 2025
    • Positioned as a leader in the Everest Group: Marketing Services PEAK Matrix® Assessment 2025
    • Positioned as a leader in the Everest Group: Talent Readiness for Next-generation Application Services PEAK Matrix® Assessment 2025
    • Recognized as a leader in HFS Horizons: The Best of Engineering Research and Development Service Providers, 2025
    • Recognized as a leader in the Constellation Research: Constellation ShortList™ Cross-Platform Agentic AI
    • Recognized as a leader in Datos: The New Era of Check Fraud Detection: A Guide to Market Solutions
    • Infosys BPM recognized as a Leader in ISG Provider Lens™ Global Capability Center (GCC) Services 2025 Study
    • Infosys BPM recognized as a Leader in ISG Provider Lens™ Procurement Services 2025 Study
    • Received the Customer Innovation Award from Databricks for delivering impactful solutions across industries
    • Received Global System Integrator of the Year-EMEA award at Stibo’s PATH Summit 2025
  • Industry & Solutions
    • Positioned as a leader in the Everest Group: Life Sciences Digital Services PEAK Matrix® Assessment 2025
    • Positioned as a leader in the Everest Group: Life Sciences Enterprise Platform Services PEAK Matrix® Assessment 2025
    • Positioned as a leader in the Everest Group: Retail Services PEAK Matrix® Assessment 2025
    • Recognized as a leader in HFS Horizons: Energy and Utilities Service Providers, 2025
    • Recognized as a leader in HFS Horizons: Intelligent Retail and CPG Ecosystems, 2025
    • Recognized as a leader in HFS Horizons: Insurance Services, 2025
    • Infosys Finacle recognized as a Market Leader in the Datos Matrix: Virtual Account Management Providers 2025 report.
    • Infosys Finacle won two awards at IBS Intelligence Digital Banking Awards 2025: ‘Regional Winners | Middle EastZand Bank & Infosys Finacle’ and ‘Segment Winner | Corporate Banking – Zand Bank & Infosys Finacle’
    • Infosys Finacle won two awards at the MEA Finance Banking Technology Awards 2025: ‘Best Composable Banking Solutions Provider of the Year’ and ‘Best Corporate Banking Solutions Provider’
    • Infosys Finacle won four awards at Finnovex North Africa – Egypt 2025:Excellence in Banking Platform Modernization with ALEXBANK Egypt’, ‘Excellence in Seamless Banking Experiences with Export Development Bank of Egypt‘, ‘Excellence in Core Banking Transformation with Agricultural Bank of Egypt‘ and ‘Excellence in Composable Banking Platform

Read more about our Awards & Recognitions here.

About Infosys

Infosys is a global leader in next-generation digital services and consulting. Over 320,000 of our people work to amplify human potential and create the next opportunity for people, businesses and communities. We enable clients in 59 countries to navigate their digital transformation. With over four decades of experience in managing the systems and workings of global enterprises, we expertly steer clients, as they navigate their digital transformation powered by cloud and AI. We enable them with an AI-first core, empower the business with agile digital at scale and drive continuous improvement with always-on learning through the transfer of digital skills, expertise, and ideas from our innovation ecosystem. We are deeply committed to being a well-governed, environmentally sustainable organization where diverse talent thrives in an inclusive workplace.

Visit www.infosys.com to see how Infosys (NSE, BSE, NYSE: INFY) can help your enterprise navigate your next.

Safe Harbor

Certain statements in this release concerning our future growth prospects, our future financial or operating performance, and the McCamish cybersecurity incident are forward looking statements intended to qualify for the ‘safe harbor’ under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results or outcomes to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the execution of our business strategy, increased competition for talent, our ability to attract and retain personnel, increase in wages, investments to reskill our employees, our ability to effectively implement a hybrid working model, economic uncertainties and geo-political situations, technological disruptions and innovations such as Generative AI, the complex and evolving regulatory landscape including immigration regulation changes, our ESG vision, our capital allocation policy and expectations concerning our market position, future operations, margins, profitability, liquidity, capital resources, our corporate actions including acquisitions, the outcome of pending litigation, the amount of any additional costs resulting directly or indirectly from the McCamish cybersecurity incident, and the outcome of the government investigation. Important factors that may cause actual results or outcomes to differ from those implied by the forward-looking statements are discussed in more detail in our US Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2025. These filings are available at www.sec.gov. Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company’s filings with the Securities and Exchange Commission and our reports to shareholders. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law.

Infosys Limited and subsidiaries
Extracted from the Condensed Consolidated Balance Sheet under IFRS as at:

(Dollars in millions)

June 30, 2025

March 31, 2025

ASSETS

Current assets

Cash and cash equivalents

3,202

2,861

Current investments

887

1,460

Trade receivables

3,780

3,645

Unbilled revenue

1,588

1,503

Other current assets

1,787

1,890

Total current assets

11,244

11,359

Non-current assets

Property, plant and equipment and Right-of-use assets

2,223

2,235

Goodwill and other Intangible assets

1,666

1,505

Non-current investments

1,241

1,294

Unbilled revenue

262

261

Other non-current assets

811

765

Total non-current assets

6,203

6,060

Total assets

17,447

17,419

LIABILITIES AND EQUITY

Current liabilities

Trade payables

422

487

Unearned revenue

994

994

Employee benefit obligations

385

340

Other current liabilities and provisions

3,353

3,191

Total current liabilities

5,154

5,012

Non-current liabilities

Lease liabilities

693

675

Other non-current liabilities

480

477

Total non-current liabilities

1,173

1,152

Total liabilities

6,327

6,164

Total equity attributable to equity holders of the company

11,069

11,205

Non-controlling interests

51

50

Total equity

11,120

11,255

Total liabilities and equity

17,447

17,419

 

Extracted from the Condensed Consolidated statement of Comprehensive Income under IFRS for:

(Dollars in millions except per equity share data)

3 months ended
June 30, 2025

3 months ended
June 30, 2024

Revenues

4,941

4,714

Cost of sales

3,416

3,259

Gross profit

1,525

1,455

Operating expenses:

   Selling and marketing expenses

258

232

   Administrative expenses

239

229

Total operating expenses

497

461

Operating profit

1,028

994

Other income, net (3)

110

88

Profit before income taxes

1,138

1,082

Income tax expense

329

318

Net profit (before non-controlling interest)

809

764

Net profit (after non-controlling interest)

809

763

Basic EPS ($)

0.20

0.18

Diluted EPS ($)

0.19

0.18

NOTES:

  1. The above information is extracted from the audited condensed consolidated Balance sheet and Statement of Comprehensive Income for the quarter ended June 30, 2025, which have been taken on record at the Board meeting held on July 23, 2025.
  2. A Fact Sheet providing the operating metrics of the Company can be downloaded from www.infosys.com.
  3. Other income is net of Finance Cost.

IFRS-INR Press Release: https://www.infosys.com/investors/reports-filings/quarterly-results/2025-2026/q1/documents/ifrs-inr-press-release.pdf
Fact sheet: https://www.infosys.com/investors/reports-filings/quarterly-results/2025-2026/q1/documents/fact-sheet.pdf